Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

47.15-4.30 (-8.36%)

As of 1:03PM EST. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	51.45
Open	50.62
Bid	47.27 x 800
Ask	47.39 x 800
Day's Range	46.45 - 50.79
52 Week Range	12.71 - 56.40
Volume	1,982,896
Avg. Volume	1,333,813

Market Cap	6.378B
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	51.81
EPS (TTM)	0.91
Earnings Date	May 10, 2021 - May 14, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	47.36

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

PR Newswire
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027 (the "Convertible Notes"). The Convertible Notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company granted an option to the initial purchasers to purchase up to an additional $105 million aggregate principal amount of Convertible Notes.
- Harvest One Announces C$4 Million Bought Deal Equity Unit Financing
  GlobeNewswire
- LMP Announces $20 Million Private Placement of Series A Convertible Preferred Stock
  GlobeNewswire
Motley Fool
Why Halozyme Therapeutics Is Trading 14% Higher Today
Halozyme Therapeutics (NASDAQ: HALO) was well in double-digit territory on Wednesday, as its stock was up by over 14% in mid-afternoon trading. For its fourth quarter of 2020, Halozyme earned $121.7 million in revenue, more than double the $53.7 million of the year-ago quarter. Fueled by royalty payments that are expected to roughly double, revenue should come in at $375 million to $395 million for 2021 -- meaning at least a 40% improvement over the 2020 tally.
- Why Anaplan Stock Is Tanking Today
  Motley Fool
- Bilibili’s 4Q Sales Beat Analysts’ Estimates; Shares Rise 3.8%
  SmarterAnalyst
Motley Fool
Halozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call Transcript
HALO earnings call for the period ending December 31, 2020.